Lund, Sweden, 2013-08-27 07:00 CEST (GLOBE NEWSWIRE) --
EXINI Diagnostics AB and FUJIFILM RI Pharma Co Ltd. have signed a five-year contract. FUJIFILM RI Pharma is given exclusive rights for the software EXINI heart on the Japanese market. In conjunction, the present contract for EXINI boneBSI has been extended for an additional five years. EXINI receives 28.4 MSEK for the licence agreements and a no-limit bonus. The projection for EXINI heart is expected to match EXINI boneBSI´s, thus rendering EXINI approximately 20 MSEK in bonuses for the contract period.
EXINI and FUJIFILM RI Pharma have cooperated successfully over the past few years, implementing EXINI BoneBSI on the Japanese market. During 2012, FUJIFILM RI Pharma reviewed the software EXINI heart and conducted extensive tests in hospitals throughout Japan. The results have been more than satisfactory. Discussions exploring an expansion of current agreements have resulted in the signing of a new five-year agreement for EXINI heart and an extension for EXINI boneBSI.
“We are strengthening our presence on the Japanese market through our successful collaboration with well-renowned FUJIFILM RI Pharma. This contract is the result of a time-consuming and extensive process where FUJIFILM RI Pharma has reviewed our software EXINI heart. In addition to this, EXINI and FUJIFILM RI Pharma collaborate in an effort to establish BSI (Bone Scan Index) as the global standard for assessing progressed prostate, breast and lung cancer. Together, we will be able to provide urologists and oncologists with a new effective tool for monitoring the development of these types of cancer”, comments Magnus Aurell, CEO, EXINI Diagnostics AB.
”With this agreement, we aim to further enhance our profile as a science oriented company on the Japanese nuclear medicine market”, comments Yoshirou Kumano, President and CEO, FUJIFILM RI Pharma Co Ltd.
”Heart scintigraphy, looking at the market value, is the dominant examination method within the field of Nuclear Medicine. It is a proven method for assessing thrombosis (blood clots) in the circulatory system supplying the heart. Competing products show problems defining small (female and Asian) hearts thus impeding a more accurate choice of treatment. EXINI heart solves these problems both effectively and innovatively,” comments Prof. Lars Edenbrandt, Founder and Scientific Director, EXINI Diagnostics AB.
For more information, please contact: Magnus Aurell, CEO Phone: +46 46 286 54 25 E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ) EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis using artificial intelligence interpreting medical radiology images providing diagnostic suggestions. In this way the system is used as a decision support for diagnosing doctors. EXINI develops products for diagnosing some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 500 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser.
________________________________________________________________________ EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
